Infectious laryngotracheitis: Etiology, epidemiology, pathobiology, and advances in diagnosis and control - a comprehensive review.

Infectious laryngotracheitis (ILT) is a highly contagious upper respiratory tract disease of chicken caused by a Gallid herpesvirus 1 (GaHV-1) belonging to the genus Iltovirus, and subfamily Alphaherpesvirinae within Herpesviridae family. The disease is characterized by conjunctivitis, sinusitis, oculo-nasal discharge, respiratory distress, bloody mucus, swollen orbital sinuses, high morbidity, considerable mortality and decreased egg production. It is well established in highly dense poultry producing areas of the world due to characteristic latency and carrier status of the virus. Co-infections with other respiratory pathogens and environmental factors adversely affect the respiratory system and prolong the course of the disease. Latently infected chickens are the primary source of ILT virus (ILTV) outbreaks irrespective of vaccination. Apart from conventional diagnostic methods including isolation and identification of ILTV, serological detection, advanced biotechnological tools such as PCR, quantitative real-time PCR, next generation sequencing, and others are being used in accurate diagnosis and epidemiological studies of ILTV. Vaccination is followed with the use of conventional vaccines including modified live attenuated ILTV vaccines, and advanced recombinant vector vaccines expressing different ILTV glycoproteins, but still these candidates frequently fail to reduce challenge virus shedding. Some herbal components have proved to be beneficial in reducing the severity of the clinical disease. The present review discusses ILT with respect to its current status, virus characteristics, epidemiology, transmission, pathobiology, and advances in diagnosis, vaccination and control strategies to counter this important disease of poultry.

The effect of vaccination of pullets against Ornithobacterium rhinotracheale infection.

The effect of vaccination of chickens with different inactivated vaccines against experimental Ornithobacterium rhinotracheale challenge was investigated. Eight different vaccines, with different inactivating substances (Formalin and thiomersal) and with or without adjuvant (mineral oil, alum and aluminium hydroxide gel), were produced. Following vaccination of experimental chickens at week 8 with formalin-inactivated mineral oil adjuvant bacterin, the mean O. rhinotracheale antibody titres rose to 5.88 2log 21 days after primary vaccination and enhanced to a titre of 6.59 2log 21 days after booster vaccination. The bacterin in mineral oil adjuvant induced the highest serologic response and a significant decrease of lesions such as air sacculitis and pneumonia in vaccinated birds compared with the unvaccinated challenge control birds. The bacterin in either alum or aluminium hydroxide gel adjuvant induced a moderate serologic response and a decrease of lesions compared with the unvaccinated challenge controls. The study showed that vaccination of layer chicken at the eighth week followed by a booster dose at the 12th week of age can effectively protect against O. rhinotracheale infections.